Hutchmed (China) Limited (HCM) ORD USD0.10
Share news, reports & tips
13 July 2021 15:42
(Sharecast News) - Hutchmed China announced the first commercial sale in China of 'Orpathys', or savolitinib, on Tuesday, which is its "oral, potent, and highly-selective" small molecule...
18 June 2021 08:52
(Sharecast News) - Hutchmed China announced the launch of its Hong Kong public offering on Friday, as part of its global offering of 104 million new shares, proposing the primary listing of its ordinary...
4 September 2020 14:13
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, said on Friday that it has initiated 'FRESCO-2' - a phase 3 registration study of 'fruquintinib' for the treatment of...
24 July 2020 15:45
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated a phase 1 study of 'HMPL-306', it announced on Friday, in patients with hematological malignancies in China.
18 June 2020 09:18
(Sharecast News) - Hutchison China MediTech, trading as 'Chi-Med', announced on Thursday that the US Food and Drug Administration (FDA) has granted 'fast track designation' for the...
9 June 2020 14:06
(Sharecast News) - Hutchison China MediTech, trading as 'Chi-Med', announced on Tuesday that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company (HBYS) - its 50-50 joint venture with...
10 February 2020 07:36
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced the availability of updated results from the phase 2 'CALYPSO' study of the savolitinib and 'Imfinzi'...
20 January 2020 16:00
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee of the phase 3 pivotal study of surufatinib in advanced neuroendocrine...
20 December 2019 15:48
(Sharecast News) - Hutchison China MediTech announced on Friday that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted 'Priority...
10 October 2019 15:45
(Sharecast News) - Hutchison China Meditech on Thursday confirmed the expansion of its tumour treatment collaboration agreement with Innovent Biologics Inc..
4 October 2019 15:21
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated an international phase 1 and 1b study of 'HMPL-523' - its novel spleen tyrosine kinase inhibitor - in patients with...
23 August 2019 11:25
(Sharecast News) - Hutchison China MediTech has launched a clinical trial of HMPL-523, a novel spleen tyrosine kinase inhibitor, in patients with immune thrombocytopenia, an autoimmune disorder that can lead...
Company announcements Announcements
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2021. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.